



OPEN ACCESS

EDITED AND REVIEWED BY
Xianming Lin,
New York University, United States

*CORRESPONDENCE
Thomas V. McDonald,
thomasmcdonald@usf.edu

SPECIALTY SECTION
This article was submitted to Cardiac
Electrophysiology,
a section of the journal
Frontiers in Physiology

RECEIVED 20 June 2022
ACCEPTED 26 July 2022
PUBLISHED 31 August 2022

CITATION
Yang J, Argenziano MA,
Burgos Angulo M, Bertalovitz A,
Beidokhti MN and McDonald TV (2022),
Corrigendum: Phenotypic variability in
iPSC-induced cardiomyocytes and
cardiac fibroblasts carrying diverse
LMNA mutations.
Front. Physiol. 13:974151.
doi: 10.3389/fphys.2022.974151

COPYRIGHT
© 2022 Yang, Argenziano, Burgos
Angulo, Bertalovitz, Beidokhti and
McDonald. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Phenotypic variability in iPSC-induced cardiomyocytes and cardiac fibroblasts carrying diverse LMNA mutations

Jiajia Yang¹, Mariana A. Argenziano², Mariana Burgos Angulo¹, Alexander Bertalovitz², Maliheh Najari Beidokhti² and Thomas V. McDonald^{1,2*}

¹Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, United States, ²Heart Institute, Department of Medicine (Division of Cardiovascular Sciences), Morsani College of Medicine, University of South Florida, Tampa, FL, United States

KEYWORDS

LMNA, dilated cardiomyopathy, induced pluripotent stem cell, cardiomyocytes, cardiac fibroblasts, connexin 43

A Corrigendum on Phenotypic variability in iPSC-induced cardiomyocytes and cardiac fibroblasts carrying diverse LMNA mutations

by Yang, J., Argenziano, M. A., Burgos Angulo, M., Bertalovitz, A., Beidokhti, M. N., McDonald, T. V. *Front Physiol.* (2021). 12:778982. doi: [10.3389/fphys.2021.778982](https://doi.org/10.3389/fphys.2021.778982)

In the published article, there was an error in **Figure 1** as published. In panel B, ALP staining pictures for R335Q and R377H were inadvertently mislabeled, which needs to be replaced. R335Q shows overlap with M1I, and R377H shows overlap with R541C. The corrected **Figure 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 1

Differentiation and characterization of induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iCMs) and cardiac fibroblasts (iCFs). **(A)** Sanger sequencing validates the presence of the individual mutation. **(B)** Representative staining of iPSCs expressing pluripotency markers SOX2 (green) and TRA-1-60 (red), SSEA4 (green), OCT4 (red), and alkaline phosphatase. Nuclei were stained with DAPI (blue). **(C)** Schematic of cardiac differentiation using STEMdiff™ Cardiomyocyte Differentiation kit. **(D)** Immunostaining of cardiac troponin T positive cardiomyocytes. **(E)** Workflow to induce cardiac fibroblasts using small molecule-based protocols. **(F)** Immunostaining of cardiac fibroblast specific marker, vimentin. Scale bar, 100 μm.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.